Correction

With regard to the article in the April 2017 issue entitled ''Tofacitinib relieves symptoms of stimulator of interferon genes (STING)–associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173" (J Allergy Clin Immunol 2017;139:1396-9), the authors wish to amend the funding support section to state "A portion of this study was supported by grants from the Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry for Health and Welfare, Republic of Korea (HI12C0066; to J.-H.C.), and the Brain Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2014M3C7A1046049; to J.-H.C.).

http://ift.tt/2qJg9jz